美国食品药品监督管理局公开研讨会总结——应对吸入性抗真菌药物研发中的挑战
美国食品药品监督管理局于2020年9月25日召开研讨会,召集肺医学与感染病学专家讨论吸入性抗真菌药物研发面临的多重挑战,包括非临床感染模型不足、患者群体高度异质、真菌病患病率低、临床试验入组标准难界定及缺乏稳健终点,并探讨监管激励与组合吸入装置等议题。
要点
- 吸入性抗真菌药物目前均未获批,疗效欠佳且不良反应较多。
- 耐药病原体出现是日益受关注的问题。
- 研发挑战包括非临床模型不足、患者异质、患病率低、入组标准难定及终点缺乏。
核心结论
- 吸入性抗真菌药物研发面临非临床模型不足、患者群体高度异质、真菌病患病率低、临床试验入组标准难界定及缺乏稳健临床终点等多重挑战。
研究设计与样本
- 美国食品药品监督管理局于2020年9月25日召开公开研讨会,召集来自学术界、产业界及其他政府机构的肺医学与感染病学专家。
主要发现
- 目前临床使用的吸入性抗真菌疗法均未获批,疗效欠佳,且与相当多的不良反应相关。
- 耐药病原体的出现也是日益受关注的问题。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allergic bronchopulmonary aspergillosis and invasive fungal diseases represent distinct infectious entities that cause significant morbidity and mortality. Currently, administered inhaled antifungal therapies are unapproved, have suboptimal efficacy, and are associated with considerable adverse reactions. The emergence of resistant pathogens is also a growing concern. Inhaled antifungal development programs are challenged by inadequate nonclinical infection models, highly heterogenous patient populations, low prevalence rates of fungal diseases, difficulties defining clinical trial enrollment criteria, and lack of robust clinical trial endpoints. On 25 September 2020, the US Food and Drug Administration (FDA) convened a workshop with experts in pulmonary medicine and infectious diseases from academia, industry, and other governmental agencies. Key discussion topics included regulatory incentives to facilitate development of inhaled antifungal drugs and combination inhalational devices, limitations of existing nonclinical models and clinical trial designs, patient perspectives, and industry insights.
引用
- Jjingo CJ, Bala S, Waack U, et al. Food and Drug Administration Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug Development. Clin Infect Dis. 2024. PMID: 37802928. doi:10.1093/cid/ciad607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。